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Abstract
Background: Polycystic ovary syndrome (PCOS) is frequently associated with hypovitaminosis D. Vitamin D is
endowed with pleiotropic effects, including insulin resistance (IR) and apoptotic pathway. Disruption of the
complex mechanism that regulated ovarian apoptosis has been reported in PCOS. Phosphoprotein enriched in
diabetes gene product (PED/PEA-15), an anti-apoptotic protein involved in type 2 diabetes mellitus (T2DM), is
overexpressed in PCOS women, independently of obesity. Leptin-to-adiponectin ratio (L/A) is a biomarker of IR and
low-grade inflammation in PCOS. The aim of the study was to investigate the levels of 25-hydroxy vitamin D (25
(OH)D), and L/A, in association with PED/PEA-15 protein abundance, in both lean and overweight/obese (o/o)
women with PCOS.
Patients and Methods: PED/PEA-15 protein abundance and circulating levels of 25(OH)D, L/A, sex hormone-
binding globulin, and testosterone were evaluated in 90 untreated PCOS patients (25 ± 4 yrs; range 18-34) and 40
healthy controls age and BMI comparable, from the same geographical area. FAI (free androgen index) and the
homeostasis model assessment of insulin resistance (HoMA-IR) index were calculated.
Results: In o/o PCOS, 25(OH)D levels were significantly lower, and L/A values were significantly higher than in lean
PCOS (p < 0.001), while there were no differences in PED/PEA-15 protein abundance. An inverse correlation was
observed between 25(OH)D and BMI, PED/PEA-15 protein abundance, insulin, HoMA-IR, FAI (p < 0.001), and L/A (p
< 0.05). At the multivariate analysis, in o/o PCOS L/A, insulin and 25(OH)D were the major determinant of PED/PEA-
15 protein abundance (b = 0.45, b = 0.41, and b = -0.25, respectively).
Conclusions: Lower 25(OH)D and higher L/A were associated to PED/PEA-15 protein abundance in PCOS,
suggesting their involvement in the ovarian imbalance between pro-and anti-apoptotic mechanisms, with high L/A
and insulin and low 25(OH)D levels as the main determinants of PED/PEA-15 protein variability. Further studies,
involving also different apoptotic pathways or inflammatory cytokines and granulosa cells are mandatory to better
define the possible bidirectional relationships between 25(OH)D, PED/PEA-15 protein abundance, leptin and
adiponectin in PCOS pathogenesis.
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Obesity, predominantly intra-abdominal visceral adipose
tissue, is observed in 30%-75% of women with polycystic
ovary syndrome (PCOS) [1], with hyperandrogenism
and insulin resistance (IR) as other common features of
this syndrome [2]. Obesity is considered to be a risk fac-
tor for hypovitaminosis D [3]. A number of cross-sec-
tional studies have evidenced the association between
obesity, hypovitaminosis D and PCOS cohorts [4-8],
although hypovitaminosis D have been considered as
the consequence of obesity and IR per se [7].
Vitamin D is endowed with pleiotropic effects on a
wide spectrum of intracellular regulatory mechanisms,
including insulin metabolism [9], or intrinsic apoptotic
pathway, on both classical and nonclassical tissues, such
as ovary [10]. Dysregulation of the complex mechanism
that regulated ovarian apoptosis has been reported in
PCOS [11].
Phosphoprotein enriched in diabetes gene product
(PED/PEA-15) is an anti-apoptotic protein involved in
IR and type 2 diabetes mellitus (T2DM) [12]. We pre-
viously reported that PED/PEA-15 is overexpressed in
T2DM patients [13] and in PCOS women [14]. In both
groups this association was independent of obesity, thus
suggesting that PED/PEA-15 overexpression might
represent a T2DM or PCOS specific feature, likely
linked to IR, although also different pathogenetic
mechanisms influencing PED/PEA -15 expression in
PCOS, such as apoptosis, have not been excluded.
Circulating levels of leptin and adiponectin, two adipose
tissue-derived hormones with opposing associations with
the metabolic syndrome (MetS) and coronary heart dis-
ease, are altered in PCOS [15], thus contributing through
the low-grade chronic inflammation to the long-term
metabolic consequence of the syndrome [16], and possibly,
to the dysregulation between apoptotic and antiapoptotic
mechanisms [17]. Finally, the ratio of leptin-to-adiponectin
(L/A), has been reported to represent a better marker for
obesity, IR, and MetS than each single adipokine [18], in
particular in female population [19]. Although there is still
some debate, a number of recent studies supported a role
for L/A as a biomarker of both IR and low-grade inflam-
mation also in women with PCOS [20].
Taking into account their involvement in obesity and
apoptosis, the aim of our study was to investigate the
balance between circulating levels of 25-hydroxy vitamin
D (25(OH)D), leptin, and adiponectin, and PED/PEA-15
protein abundance, in both lean and overweight/obese
(o/o) women with PCOS.
Materials and methods
Study design
This is an observational clinical study based on the eva-
luation of 25(OH)D, leptin, and adiponectin in both
lean and overweight/obese (o/o) women with PCOS.
The procedures used were in accordance with the
guidelines of the Helsinki Declaration on human experi-
mentation. The study was conducted without support
from the pharmaceutical industry, after approval by the
institutional review board of the University of Naples,
Italy. The purpose of the protocol was explained to both
the patients and the controls, and written consent was
obtained at the beginning of the study.
Subjects
Ninety untreated PCOS patients (25 ± 4 yrs; range 18-
34) were consecutively admitted to the Endocrinology
Unit of the Department of Molecular and Clinical Endo-
crinology and Oncology of the Federico II University of
Naples (Italy), and enrolled in this observational clinical
study according to following inclusion criteria: pre-
menopausal women, with a strict age range (20-40 yr)
with diagnosis of PCOS; anovulatory oligo-amenorrhea;
comparable clinical/biochemical hyperandrogenism; cau-
casian ethnicity. All subjects included in the study
resided in the Naples metropolitan area (latitude 40° 49’
N; elevation 17 m) and were evaluated from March
trough June 2011.
To further minimize subjects variability, the presence
of T2DM or abnormal glucose tolerance was excluded
by the oral glucose tolerance test (OGTT). Other exclu-
sion criteria for all subjects were: smoking or alcohol
consumption, pregnancy, hypothyroidism, hyperprolacti-
nemia, Cushing’s syndrome, non-classical congenital
adrenal hyperplasia; previous (within the last 6 months)
use of oral contraceptives, glucocorticoids, anti-andro-
gens, ovulation induction agents, anti-obesity drugs, or
other hormonal drugs. None of the subjects was affected
by any neoplastic, metabolic, hepatic, and cardiovascular
disorder or other concurrent medical illness (i.e. renal
disease, and malabsorptive disorders). Moreover, those
with acute inflammations based on medical history, phy-
sical examination, and routine laboratory tests, including
measurement of body temperature, white blood cell
count (WBC) and urinalysis, were excluded. The diagno-
sis of PCOS was made according to the diagnostic cri-
teria for PCOS [21]. All PCOS women enrolled in the
study had clinical and/or biochemical hyperandrogenism
with IR. Forty young women, among clerks, and medical
and paramedical personnel of the Department of Mole-
cular and Clinical Endocrinology and Oncology of the
University “Federico II” of Naples, age and BMI compar-
able with the patients, from the same geographical area,
with regular menstrual cycles (defined as 26-32 days in
length), agreed to participate in this study and were
used as controls. Exclusion criteria for controls were
the same of the patients. All participants gave their
informed consent before enrolment.
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The ovulatory state was investigated by pelvic or trans-
vaginal ultrasonography (TV-USG) and plasma proges-
terone (P) levels. Both procedures were performed
during the luteal phase of the menstrual cycle (7 days
before the expected menses). The presence of fluid in
t h ec u l - d e - s a ca tp e l v i co rT V - U S Ga n dap l a s m aP
assay >32 nmol/l (>10 ng/ml) were considered to be the
criteria to show that ovulation had occurred [22]. The
controls were not genetically related to the PCOS group
and without family history of diabetes.
Hirsutism was assessed using the Ferriman-Gallwey
(FG)-score, with a score >8 indicative of hyperandrogen-
ism [23]. A progesterone challenge test (100 mg natural
progesterone im) was performed, which induced uterine
bleeding in all PCOS women. The normal glucose
response to the OGTT was defined according to the
“Report of the Expert Committee on the diagnosis and
classification of diabetes mellitus” [24].
All anthropometric measurements were taken with
subjects wearing only light clothes and without shoes. In
each woman, weight and height were measured to calcu-
late the BMI [weight (kg) divided by height squared
(m
2), kg/m
2]. Height was measured to the nearest cm
using a wall-mounted stadiometer. Body weight was
determined to the nearest 50 g using a calibrated bal-
ance beam scale. The degree of normal weight, over-
weight, or obesity was established on the basis of BMI
cut-off points of 18-24.9 (lean subjects), 25-29.9, 30-
34.9, 35-39.9 and > 40 kg/m
2, respectively (o/o).
Assays
Blood samples, obtained between 08:00 h and 09:00 h
from an ante-cubital vein after an overnight fast, with
the patient in the resting position, were promptly centri-
fuged, and serum separated and stored at -20°C until
assay. The OGTT was performed using 75 g dextrose.
Blood samples were obtained at 0, 30, 60, 90, 120 min
for plasma glucose and insulin measurements. Fasting
plasma glucose (FPG) levels were determined by the glu-
cose oxidase method immediately after the OGTT. Cir-
culating levels of 25(OH)D (LIAISON; DiaSorin,
Saluggia (VC), Italy), fasting plasma insulin (FPI), sex
hormone-binding globulin (SHBG), and testosterone (T)
levels (Immulite, Diagnostic Products Co, Los Angeles,
CA; n.v. 0.2-1.2 nmol/l) were measured by solid-phase
chemiluminescent enzyme immunoassays. The intra-
assay coefficients (CV) of variations were less than 5·5%
for the 25(OH)D, insulin, and SHBG assays, and 10%
for total T assay. FAI (free androgen index) was calcu-
lated as an expression of peripheral androgen activity
and estimated as total T and SHBG serum concentra-
tion, according to the formula FAI = T (nmol/l)/SHBG
(nmol/l) × 100. Leptin and total adiponectin (low,
middle, and high molecular weight) levels were deter-
mined with commercially available enzyme-linked
immunosorbent assay (ELISA) kits (AviBion: Orgenium
Laboratories, Helsinki, Finland), with sensitivity 1 and 3
ng/ml, respectively; intra- and inter- assay CVs were less
than 10% and 12%, respectively, for adiponectin and lep-
tin. Vit D deficiency and insufficiency were defined as
10-30 and <10 ng/ml, respectively. The homeostasis
model assessment of insulin resistance (HoMA-IR)
index was calculated from FPG and FPI according to
the report by the formula [FPI (μU/ml) × FPG (mmol/
l)]/22.5] [25]. As a stringent measure of IR, a value of
HoMA-IR > 2.0 was set (deriver by the mean ± 2 SD of
our lean population), in accordance with a previuos cut-
off [26].
PED/PEA-15 protein levels were measured in WBC
l y s a t e so b t a i n e df r o m1 0t o1 2m lo ff r e s h l yc o l l e c t e d
uncoagulated whole blood, after separation with dextran
6%, using Western blot analysis, as previously reported
[13]. For Western blot analysis WBC were solubilized at
4 C in TAT buffer, centrifuged at 500 g for 20 min, and
supernatant fractions were stored at -20°C until used.
The amount of 50 μg of lysate proteins were heated at
100°C in Laemmli buffer. Proteins were separated by
15% SDS-PAGE and then transferred to 0·45 mm
Immobilon-P membranes (Millipore, Bedfort, MA). Fil-
ters were probed with PED/PEA-15 antiserum at 1:2000
dilution, revealed by enhanced chemiluminescence and
autoradiography. The protein bands were quantified by
laser densitometry and expressed as arbitrary units. As
reported previously [13], PED/PEA-15 protein levels in
WBC detected by Western blot analysis, correlated
strongly with mRNA detected by real time RT-PCR (p <
0.001). In addition, PED/PEA-15 protein stability was
also assessed by repeated testing, at 2, 4, and 6 months
after storage, displaying intra- and inter-assay coeffi-
cients of variation <8 and <15%, respectively.
Statistical analysis
All results are expressed as mean ± SD. Fasting 25(OH)
D, insulin, PED/PEA-15 protein abundance, leptin, and
adiponectin values were not normally distributed and
have been logarithmically transformed. Differences
between lean and overweight/obese subjects in both
PCOS and Control women were analysed by unpaired t
test. Bivariate correlations between variables were exam-
ined using Pearson’s correlation coefficient. Only vari-
ables significant on univariate analysis were included in
the multivariate analysis. Three multiple linear regres-
sion analysis (stepwise model, p to include <0.005, p to
remove >0.1, maxstep 15), were calculated with PED/
PEA-15, as dependent variable and BMI, insulin, 25
(OH)D, L/A and FAI as independent variables consider-
ing PCOS women as a whole, or according to BMI (lean
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erance of 0.2 were excluded. Values ≤5% were consid-
ered statistically significant. Data were stored and
analysed using the Statistical Package for Social Science
program (SPSS, release 13·01, Chicago, IL).\\
Results and Discussion
Metabolic and hormonal characteristics of the study
population were reported in Table 1. Testosterone levels
and FG score in PCOS women were 2.8 ± 1.1 nmol/l
and 16 ± 6, respectively. Grouping PCOS women
according to BMI, there were 42 lean and 48 o/o sub-
jects. Subgroup analysis of o/o and lean women revealed
differences between groups. In particular, apart from the
expected differences in insulin, HoMA-IR, and andro-
gens, 25(OH)D and adiponectin levels were significantly
lower, while leptin levels and L/A values were signifi-
cantly higher in o/o PCOS compared with lean PCOS.
No differences in PED/PEA-15 protein abundance were
evident between lean and o/o PCOS women.
Correlations between variables in the study popula-
tion were reported in Figure 1. In PCOS women, an
inverse correlation was observed between 25(OH)D
and BMI (a), PED/PEA-15 protein abundance (b), insu-
lin (c), HoMA-IR (d), and FAI (e) (r= -0.474, -0.553,
-0.380, -0.407, -0.374, respectively; p < 0.001), and L/A
(f) (r= -0.306, p < 0.05). At the multivariate analysis,
with PED/PEA-15 protein abundance as dependent
variable only insulin and 25(OH)D remained in the
model (b =0 . 3 9a n db = -0.32, respectively) (Table 2).
The results of the analysis were different, however, in
the two group of PCOS women, as the major determi-
nants of PED/PEA-15 protein abundance were BMI
and insulin in lean PCOS (b =0 . 6 5a n db =0 . 2 6 ,
respectively) (Table 3), and L/A, insulin and 25(OH)D
in o/o PCOS (b = 0.45, b =0 . 4 1a n db = -0.25, respec-
tively) (Table 4).
Our data evidenced that in women with PCOS low
levels of 25(OH)D and PED/PEA-15 protein abundance
are associated to high insulin, HoMA-IR, and L/A
values. According to previous data hypovitaminosis D
was evident in all PCOS women, with 25(OH)D levels
being significantly lower in o/o than in lean PCOS
women. Insulin was the major determinant of PED/
PEA-15 protein abundance, explaining about 26% of
PED/PEA-15 protein abundance variability, while 25
(OH)D levels added another 7% of its variability. In that
our data confirmed the association between insulin and
25(OH)D [7], but evidenced also a novel association
between 25(OH)D, PED/PEA-15 protein abundance, and
L/A in PCOS women.
A number of cross-sectional studies have evidenced
the association between hypovitaminosis D and PCOS
cohorts [4-8], although low serum 25(OH)D concentra-
tions have been considered as the consequence of obe-
sity and IR per se [5-7]. Also an altered L/A has been
already reported in PCOS women, as a biomarker of
both IR and low-grade inflammation [15,17,27,28]. How-
ever, to the best of our knowledge, all these variables in
PCOS women have been investigated in the setting of
IR or MS, while it is well-known that either 25(OH)D
or low-grade inflammation display strict relationships
with apoptotic and antiapoptotic mechanisms [29].
Thus, the association of 25(OH)D and L/A ratio with
the anti-apoptotic protein PED/PEA-15 might suggest a
different scenario in PCOS women.
Table 1 Metabolic and endocrine characteristics of the study population grouped according to BMI.
PCOS women (90 subjects) Controls (40 subjects)
Lean
(42)
Overweight/Obese
(48)
p Lean
(20)
Overweight/Obese
(20)
p
Age (yrs) 24.1 ± 4.6 24.8 ± 4.0 NS 23.9 ± 3.6 25.4 ± 4.6 NS
BMI 22.1 ± 2.6 33.1 ± 5.8 <0.001 22.1 ± 1.6 34.9 ± 4.1 <0.001
25(OH)D (ng/ml) 15.1 ± 7.6 11.1 ± 5.8 0.021 48.9 ± 11.3 10.2 ± 4.7 <0.001
PED/PEA-15 290 ± 102 295 ± 113 0.745 153 ± 29 177 ± 47 0.092
Leptin (ng/ml) 25.8 ± 6.6 40.3 ± 9.1 <0.001 9.9 ± 4.8 29.4 ± 6.6 0.003
Adiponectin (ng/ml) 13.2 ± 5.7 9.4 ± 6.3 <0.001 17.4 ± 3 11.6 ± 2.5 <0.001
Insulin (μUI/ml) 11.9 ± 4.6 17.1 ± 9.4 0.014 7.6 ± 1.9 11.5 ± 2.0 <0.001
Leptin-to-adiponectin ratio 2.5 ± 1.8 5.8 ± 2.7 <0.001 0.6 ± 0.4 2.0 ± 1.7 <0.001
HoMA-IR 2.4 ± 1 3.8 ± 2.2 <0.001 1.4 ± 0.3 2.2 ± 0.3 <0.001
SHBG (nmol/l) 45.7 ± 7.2 41.3 ± 6.9 0.001 69.5 ± 3.1 63.3 ± 10.5 0.016
FAI 4.6 ± 0.8 8.7 ± 3.8 <0.001 0.8 ± 0.2 0.9 ± 0.2 0.05
Data are reported as mean ± SD. BMI, body mass index; 25(OH)D, 25(OH) Vitamin D; PED/PEA-15, PED/PEA-15 abundance; HoMA-IR, homeostasis model
assessment of insulin resistance; SHBG, sex hormone binding globulin; FAI, free androgen index; FG, Ferriman-Gallwey. PED/PEA-15 protein levels are expressed as
arbitrary units. Fasting 25(OH)D, insulin, PED/PEA-15 protein abundance, leptin, and adiponectin values were not normally distributed and have been
logarithmically transformed. Differences between lean and overweight/obese subjects in both PCOS and Control women were analysed by unpaired t test.
Controls were age and BMI comparable.
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reported to account PCOS appearance [11,30,31], with
hyperandrogenism as one of the proposed mechanisms
affecting the balance between the ovarian expression of
pro and anti-apoptotic proteins [32]. In particular, follicu-
lar atresia is associated with an imbalance in the antiapop-
totic effect of the Bcl-2 family members [33], while
gonadotropin treatment inhibits granulosa cell apoptosis
and follicular atresia through the reduction of the expres-
sion of the proapoptotic protein Bax [32]. Recent studies
have revealed that Vit D is involved in the control of var-
ious cellular processes, including apoptosis, via Bcl-family
up-regulation and Bax down-regulation, but the mechan-
isms underlying this action have not been fully explored
[10,34]. Similarly, leptin and adiponectin exherted opposite
effects also in the complex control of apoptosis-antiapop-
tosis mechanisms. In particular, leptin acts as a mitogenic
factor in a variety of cell types, including ovary [35], where
it has been found to interfere with ovulation rate [36]. On
the other hand, adiponectin, whose receptors are
expressed in ovary in human [37], has been recently
reported to activate the Mitogen-Activated Protein Kinase
(MAPK) cascade in granulosa cells, in the context of the
classical adiponectin anti-apoptotic effects [37-39].
Table 2 Multiple linear regression analysis in PCOS
women.
Independent variables:
BMI, insulin, 25(OH)D, L/A, FAI
Step Variables inserted in the model p R
2
1 insulin <0.001 0.26
2 insulin
25(OH)D
<0.001
0.001
0.33
Variables excluded from the model:
BMI, L/A, FAI
Variations in PED/PEA-15 abundance explained by stepwise model (p to
include < 0.05, p to remove > 0.1), with selected variables in PCOS women (n
= 90). BMI, body mass index; 25(OH)D, 25(OH) Vitamin D; PED/PEA-15, L/A,
leptin-to-adiponectin ratio; FAI, free androgen index.
Table 3 Multiple linear regression analysis in lean PCOS
women.
Independent variables:
BMI, insulin, 25(OH)D, L/A, FAI
Step Variables inserted in the model p R
2
1 BMI <0.001 0.52
2 BMI
insulin
<0.001
0.021
0.58
Variables excluded from the model:
25(OH)D, L/A, FAI
Variations in PED/PEA-15 abundance explained by stepwise model (p to
include < 0.05, p to remove > 0.1) in lean PCOS women (n = 42). BMI,b o d y
mass index; 25(OH)D, 25(OH) Vitamin D; PED/PEA-15, L/A, leptin-to-adiponectin
ratio; FAI, free androgen index.
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Figure 1 Correlations between variables in the study population. 25(OH)D, 25(OH) Vitamin D; BMI,b o d ym a s si n d e x ;HoMA-IR, homeostasis
model assessment of insulin resistance; FAI, free androgen index; L/A, leptin-to-adiponectin ratio. Fasting 25(OH)D, insulin, PED/PEA-15 protein
abundance, leptin, and adiponectin values were not normally distributed and have been logarithmically transformed. PED/PEA-15 protein bands
were quantified by laser densitometry and expressed as arbitrary units [13]. Bivariate correlations between variables were examined using
Pearson’s correlation coefficient and their values are singularly evidenced.
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and impaired L/A played an adjunctive role to insulin in
influencing the increase in the anti-apoptotic protein
PED/PEA-15 abundance and, therefore, contributing to
alter the equilibrium between anti and pro-apoptotic
factors in PCOS.
Of interest, grouping PCOS women according to BMI
there were different associations between the study vari-
ables. In particular, in lean PCOS BMI explained 52% of
PED/PEA-15 protein abundance variability, and insulin
added only another 6% of its variability; in o/o PCOS
women L/A, insulin and 25(OH)D explained 37%, 22%
and 5% of PED/PEA-15 protein abundance variability,
respectively. Thus, it is tempting to speculate that in
PCOS women, along with the progressive increase in
BMI, A/L and IR induced by increased amount of dys-
functional adipocytes are involved in the higher activa-
tion of anti-apoptotic pathways, such as PED/PEA-15
protein.
The alteration of the dynamics of the loss of preantral
follicle by atresia might contribute to increase androgen
secretion from atresic follicles, that on turn, resulted not
only in further increase in follicle atresia [32], but also
in IR and PED/PEA-15 protein abundance. In line with
hypothesis, we found opposite correlations between 25
(OH)D, PED/PEA-15 protein and L/A with FAI, the
main biochemical endocrine PCOS features. In particu-
lar, 25(OH)D exhibited an inverse, while PED/PEA-15
protein and L/A showed a positive correlation with FAI.
Apart from a clear effect of gender differences [40], the
inverse association of 25(OH)D with testosterone and
FAI in the setting of PCOS, despite some controversies
[8], and the positive association of PED/PEA-15 protein
abundance with hyperandrogenism, were according to
previously published data [14], further suggesting the
involvement of bidirectional influences between both
variables in the progression of the disease.
Due to the cross-sectional design of the study, these
results must be regarded as preliminary data and cannot
be generalized beyond the cases studied, nor we can
draw conclusions on the natural progression of these
relationships over time. Moreover, we evaluated PED/
PEA-15 protein abundance in WBC and not in ovary
cells; thus, although we previously reported that PED/
PEA-15 protein levels in WBC correlated strongly with
mRNA detected by real time RT-PCR PED/PEA- 15
protein amount in fat and in skeletal muscle tissues
[13], we need to be aware of possible unexplored differ-
ences between WBC and ovary cell PED/PEA-15 protein
expression. Taking into account that laparoscopy is not
routinely performed in PCOS for ethical considerations,
we did not obtain granulosa cells preparations from
women with PCOS in this preliminary investigation.
Conclusions
Although further studies are mandatory, involving also
different apoptotic pathways or inflammatory cytokines
and PCOS granulosa cells, the correlations between 25
(OH)D, PED/PEA-15 protein abundance, L/A ratio, and
hyperandrogenism in our sample of PCOS women, with
high insulin and low 25(OH)D levels as the main deter-
minants of PED/PEA-15 protein abundance, suggested
the involvement of all these variables in the imbalance
between pro-and anti-apoptotic factors responsible for
the increased follicular atresia in PCOS.
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